ARPA-H Awards Up to $160 Million to Advance Personalized Genetic Medicines

The Advanced Research Projects Agency for Health (ARPA-H) will award up to $160 million throughout the next five years to accelerate the development of personalized genetic medicines for rare pediatric diseases. The funding will support seven research teams through the agency's Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) Program.

The teams will develop platform technologies designed to support multiple personalized therapies and evaluate them through innovative clinical trial models. THRIVE is intended to accelerate the development and regulatory approval of treatments for life-threatening rare genetic diseases while improving scalability and patient access.